Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Clinical trial NCT06000033 · UNKNOWN
Trial details
- NCT number
- NCT06000033
- Sponsor
- Qilu Hospital of Shandong University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-10
- Primary completion
- 2024-12-31
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.